1. Introduction

The definition of asthma is constantly being modified and redefined. New knowledge derived from molecular biology and applied immunology is very valuable in interpreting how the airway becomes diseased. At the same time, new biomarkers useful for monitoring patients and detecting inflammatory airway disease are being identified. Currently, patients whose condition is included in the spectrum of inflammatory airway diseases may be reassessed and placed into subgroups so that the biotypes, or endotypes (disease) and phenotypes (patients), form new paradigms to delineate and integrate applied knowledge to this complex and heterogeneously-expressed disease. The definition of asthma and different ways of understanding the disease undergo constant review.

2. Asthma defined as an inflammatory airway disease

The definition of asthma may be established using a set of characteristics that are clinical (recurrent episodes of wheezing and dyspnea), pathophysiological (variability in airflow), or immunological (chronic inflammation) (Global Initiative for Asthma [GINA], 2009; British Thoracic Society Scottish Intercollegiate Guidelines Network [BTSSIGN], 2008). They may be found in patients or heterogeneous groups of patients who share these symptoms to a greater or lesser extent. Depending on the emphasis placed on a more specific predominant feature of airway dysfunction, the ‘nominalist’ view of the concept of asthma is more relevant. On the other hand, if several features are examined together to make the diagnosis, the more ‘essentialist’ aspect of the specific airway disease stands out [GINA, 2009; BTSSIGN 2008]. Thus, both definitions must be kept in mind when dealing with asthma, and determining an objective system of measurement for the quantifiable aspects that that make up either definition is required [Hargreave & Nair, 2009]. For decades, different methods to quantify and measure the various components of asthma (symptoms, spirometry, maximum peak flow, bronchial provocation) have been used in situations of good health or illness, highlighting the complexity involved in studying, functionally, both the normal and altered airway. Not all the defining characteristics of asthma are present in all patients; moreover, they vary greatly and are often irregular in a single patient. The therapeutic response may also be different depending on the specific pathophysiological characteristics that are predominately found [Lotvall et al., 2011]. Therefore, the classification of asthma severity by
daily medication regimen and response to treatment, as well as the different strategies and recommendations for managing patients with difficult to control asthma are essentially needed in clinical practice [Holgate & Polosa, 2006]; otherwise they are limited. New methods based on statistical physics and fluctuation analysis can be a new strategy for assessing and predicting the risk of progression of asthma [Frey & Suki, 2008], but monitoring of airway diseases also requires focus on foundations of the modern biology. Therefore, the application of new technological advancements and the disciplines applied to the study of inflammation, as well as the incorporation of new markers for diagnosis and the monitoring of patients affected by asthma, inspires optimism in the challenge to find a better conceptual understanding of asthma using a dynamic approach that continuously changes and at the same time is more significant than that achieved by mere verification.

In this chapter, specific aspects of the new contributions to the monitoring of asthma and the new research using defined groups of patients to study interrelated heterogeneous aspects of asthma will be described and discussed. These new contributions have modified the approach to grouping and reclassifying characteristics that are clinical, pathophysiological and biological as a whole, and allow for a new definition of asthma in terms of 'phenotypes' and 'endotypes' [Anderson, 2008a; Wenzel, 2006]. Although the addition of these new terms to the definition of asthma may be seen as a conceptual breakthrough, caution must be exercised. For example, new biological knowledge about the pathogenic understanding of inflammatory airway disease (IAD) requires further investigation in many aspects, including how it differs from phenotypes in chronic obstructive pulmonary disease (COPD) [Barnes, 2008], as well as in children [Spycher, 2010]. Hence, a major challenge in the field of respiratory disease today is how to adapt the definition of asthma to new scientific developments. The verification of objective 'biotypes', in terms of the development of asthma and the patients in whom they are observed, is an important conceptual advance, provided better clinical management for each patient is achieved so that the relative uniqueness of each patient with asthma can be better understood, both by the physician and the patients themselves. However, in order to define 'phenotypes' specific to patients or subgroups of patients in addition to the specific pathogenic 'endotypes' that identify them (in other words, how asthma patients become ill), it is necessary to thoroughly identify their defining characteristics. They must therefore be measured and grouped biologically and clinically in a differentiated way, even if certain aspects of the illness are the same [Lotvall et al., 2011; Moore et al., 2010].

Today's objective biological measures and markers used to better understand these biotypes are the central focus of this chapter.

3. Monitoring the airway and monitoring asthma in particular

There are a number of methods available for identifying different aspects related to the natural evolution of IAD. The contribution of each aspect is determined by providing appropriate measures and robust parameters that meet consistent methodological determinants, such as the standardization of the method used, the availability of reference values, the reproducibility of findings, and above all the application of research findings to clinical practice and the global management of patients whose situation is well-defined as well as homogeneous patients or groups of subjects. Not all biological measures studied in recent years have managed to become routinely added as a parameter with clinical value in
the management of patients. Furthermore, those used routinely provide specific and limited information only. Therefore, current research being conducted focuses more on the inflammatory aspects of the lung, rather than the classical or clinical function, because it is the central pathogenic mechanism of the disease in the airway [Fabbri et al., 2005]. Severity and control disease assessment requires a multidimensional practical approach including an inflammatory view, as was previously confirmed by some authors [Fitzpatrick et al. 2011a; Haldar et al., 2008].

Technological advancements brought about by modern molecular biology and innovative micron analysis technology applied to the study of inflammation and the pathways of oxidative, lipid, or nitric stress, for example, can allow for a better identification and definition of new parameters, inflammatory profiles, and biomarkers that are more sensitive and specific for predicting the state of progression of IAD, differences in poor outcomes, and the type of anti-inflammatory treatment best suited to manage a particular patient or patient group.

This section briefly discusses the most relevant parameters used in clinical practice for the monitoring of asthma, especially the most recent parameters that contribute greatly to the overall management of patients and other more promising parameters, from the perspective derived by direct measurement and monitoring of inflammatory activity.

3.1 Global systems of measurement for airway disease

From a clinical point of view, patients are typically monitored through the measurement of the symptoms present, questionnaires on the degree of control of the disease [Curtis et al., 1997] or the impact on quality of life related to health [Juniper et al., 2004], pathophysiological parameters such as the degree of bronchial obstruction [FEV$_1$ or PEF] [Miller, 2005], and variability [Reddel, 2006] or the degree of bronchial hyper-reactivity, both specific and nonspecific [Anderson, 2008b; Cockcroft & Davis 2006; Crapo et al., 2000; Sont et al., 1999; Sterk et al., 1993]. Each of these are more or less direct methods of measuring the clinical impact of inflammatory diseases of the airways, providing complementary information to diagnostic and therapeutic management [Fuhlbrigge, 2004; Gibson & Powell, 2004; Taylor et al., 2008] and, to a lesser degree, clinical interpretation [Frey & Suki, 2008]. They have become absolutely necessary and indispensable for the classification of the patient's and establishment of control disease. In terms of study, testing of the whole response of the total airway implies knowing several pathogenic mechanisms of disease [Bousquet et al., 2000; Leuppi et al., 2001]. Understanding how control of the severity or clinical evolution of the disease is developed retains some specific limitations that result in advantages and disadvantages. For example, the main advantage of studying bronchial hyper-responsiveness to histamine or methacholine challenge is the high negative predictive value of the test [Luks et al., 2010]. On the contrary, its presence and the severity observed indicate functional impairment of the airway. This may be interpretable in either a physiological (dysfunction, with or without an associated inflammatory basal profile) or pathological context (chronic inflammation, injury, mucosal or submucosal remodelling), which may or may not be modified by treatment once established [Hargreave et al., 1981; Rosi et al., 1999; Sont et al., 1999; van Essen-Zandvliet et al., 1994]. Recent advances in the clinical use of substances, such as adenosine or mannitol, provide additional data on the association between bronchial hyper-responsiveness, as measured by these indirect stimuli, and markers of inflammation [Polosa et al., 2000; Rutgers et al., 2000].
Other findings arising from the current radiological spectrum of diseases of the airway also provide useful data to study dynamic airway inflammation, expressed as the degree of trapped air and bronchial wall thickness [Gupta et al., 2010]. It is therefore possible to say that although the parameters and measurements discussed in this section can be applied to both asthma and COPD in order to achieve better clinical management, its meaning and clinical interpretation are often heterogeneous or variable depending on the patient, the therapy administered at the time of measurement, and the spectrum of IADs identified in the subject, both initially and over time [Avital et al., 1995; Dima et al., 2010]. Discrimination of all the spectrum of obstructive airway diseases is the goal to achieve at present time.

3.2 Direct systems of injury and repair measurement in pulmonary biology

The pathology of the airway has a clearly inflammatory pathophysiological basis, although the role this plays, both in the short term and in the long term, in the biological continuum of integrity, dysfunction, injury, and repair continues to undergo constant research. Traditionally, the gold standard in inflammatory activity has been to use various measurements and markers, both inflammatory and those of oxidative stress, obtained invasively by bronchial biopsy and bronchoalveolar lavage [Bergeron et al., 2007; Brasier et al., 2010; Hallstrand et al., 2011]. Although various parameters and histological patterns of inflammation have been identified with these techniques, many of them are shared by the anatomopathological spectrum of IAD. This causes ambiguity, both in the various pathogenic contexts in which pathophysiological interpretation is difficult and, consequently, non-pathognomonic situations in which discrimination regarding asthma or COPD occurs. Only some of these findings have demonstrated applicability to clinical care and a certain ability to differentiate or discriminate between the inflammatory pathogenic states of an underlying pathologic lesion, as in the study of bronchial remodelling [Sont et al., 1999; Sont et al., 2003], or the prevalence of the cellular profile of bronchial infiltration, as in the case of life-threatening asthma [Mauad et al., 2004; Mauad et al., 2008]. Furthermore, both techniques also have some significant limitations when carried out routinely. The first is that only one compartment of the airway is represented unless both procedures are done at the same time. The second limitation is the invasiveness of the procedure. This is an obstacle when routinely performed on the patient, despite the fact that these methods have been standardized and allow for a better visualization of the type of inflammation and anatomical injury caused by IAD in certain patients. They are also useful in studying the pathogenic mechanisms involved, as well as classifying and identifying the stage of disease [Fabbri et al., 2003; Fabbri et al., 2005; Moore et al., 2011], but the requirements of the procedure do not make them suitable for routine monitoring of the patient and are therefore generally reserved today for the systematic study of inflammation in pulmonary biology research.

The new semi-invasive methods, such as induced sputum, or non-invasive methods, such as the measurement of nitric oxide, condensation, or exhaled temperature, provide new and useful data directly from the airway that may be used in the classification of IADs and the management of patients [Popov, 2011]. Some markers derived from blood samples can also be used in assessing inflammatory disease and its systemic impact. These include eosinophil cationic proteins, as well as cationic peroxidase and leukotriens [Koh et al., 2007; Rabinovitch, 2007], but other novel systemic blood biomarkers are also promising [Verrills
et al., 2011]. The most important contributions of non-invasive methods currently used to measure inflammation of the airway and the most promising research being carried out with new applied technologies in molecular biology and immunology are discussed below.

3.2.1 Induced sputum
This semi-invasive technique is used to obtain a representative sample of bronchial secretions in the airway. Some methodological variations in the induction procedure may produce samples from a more central or peripheral compartment of the airway, providing versatility in IAD screening in terms of both central and peripheral orientation. This is characterized as such because the differential inflammatory profile obtained is reproducible and can be correctly interpreted in a clinical context. However, this is not the case in the study of the various markers of inflammation and oxidative stress obtained from the supernatant, which have strict methodological considerations and limitations in the interpretation of results [Nicholas, 2009]. Bearing this in mind, induced sputum has become the gold standard non-invasive method for measuring bronchial cell inflammation and for certain soluble markers that are identifiable and of specific dilution [Bakakos, 2011; Djukanovic 2004]. The standardization of the method and procedure, adequate safeness of the technique, good toleration by the patient, ease of use, and the obtainment of reference values have made it an essential technique in the study of complex patients who require the characterization of the bronchial inflammatory pattern in order to be managed correctly [Djukanovic, 2002]. The current characterization of the endotypes and phenotypes of patients with inflammatory airway disease, based on inflammatory cell patterns [Balzar et al., 2011; Haldar et al., 2008], and the combination of different biomarkers, such as those derived from 'esputoma' [Gray et al., 2008; Nicholas, 2006] and oxidative stress [Louhelainen et al., 2008a; Louhelainen et al., 2008b], 15-lipoxygenase pathway [Chu, et al., 2002], glutathion oxidation [Fitzpatrick et al., 2011b] or genetics and protein identification [Baines et al., 2011; Hastie et al, 2010] make sputum an indisputable protagonist in the new definition of phenotypes, the classification of patients with asthma and COPD [Fabbri et al., 2003; Fatj et al., 2009; Louis et al., 2002; Wang et al., 2011], the therapeutic management of these patients, the prediction of therapeutic response [Green et al., 2002; Jayaram et al., 2006, Caramori et al., 2005], and the evaluation of efficacy in the most recent anti-inflammatory molecules [Haldar et al, 2009; Pavord et al. 2009, van Rensen et al. 2009]. Currently, new techniques in molecular biology may be applied to the study of sputum in order to study the expression shown in the cellular response of certain subtypes of cell lines, as found for example, by studying toll-like cell receptors or local innate immunity measured by flow cytometry [Lay et al, 2011], or those derived from cell cultures [Bettiol et al., 2002], the cellular response to markers of cell migration [Dent et al., 2004], or even those obtained from the analysis of proteomics traces or esputoma [Park & Rim, 2011; Nicholas & Djukanovic, 2009], as well as the genome [Baines et al., 2011; Bisgaard et al., 2011].

3.2.2 The exhaled fraction determined singularly or in combination
The use of exhaled markers capable of reflecting a clinically useful measurement of the inflammation and oxidative stress present in the airway currently involves bronchial nitric oxide (NO) as the main marker [Barnes et al., 2010]. This measurement is reproducible and the method has been standardized [ATS/ERS, 2005]. Because its concentration is dependent on the flow and the source of production, a compartmental model of alveolar or bronchial
Origin of exhaled nitric oxide has been developed in order to study the origin of the alteration and the lung injury, situating it at a more central or peripheral level in the airway [Puckett et al., 2010]. This model allows the production variability within the spectrum of IAD and the anti-inflammatory modulation produced by the therapy administered to be studied in depth. While this method is certainly advantageous when carrying out clinical monitoring within a timeframe because of its non-invasivity, it may only be used in certain patients, i.e. those in whom the main source of NO has been identified as a clearly modifiable and dependent element of the course of inflammation with therapeutic anti-inflammatory management, or for the screening of type of activated inflammation [Anderson et al., 2011]. The use of NO in the research of no homogeneously selected patients leads to a clinically confusing interpretation in terms of its identification and therefore must be considered limited or biased under these circumstances [Dweik et al., 2010]. In addition, certain methodological considerations conditioned by the design of NO research studies regarding the cut-off used to make a management decision must be taken into account during diagnosis and treatment, i.e. conditioning the patient management strategy based on the levels of NO [Gibson, 2009; Quaedvlieg et al., 2009; Schleich et al., 2009; Schneider et al., 2009].

Other exhaled markers of the bronchial airway, such as the detection of carbon monoxide and other volatile hydrocarbon compounds, products of lipid peroxidation, have also been studied [Antczak et al., 2011]. However, a definitive standardization of methods for immediate application in a clinical context has not been achieved. Similarly, the measurement of exhaled temperature increase at the start of breathing with regard to the reference point marked during the entire period of measurement of the increase is associated with the presence of active inflammation and airway remodelling [Paredi, 2005]. This also occurs with the measurement of bronchial blood flow, estimated by mass spectrometry using the Fick principle, and the calculation of the dilution of exhaled acetylene [the initial concentration inhaled is known]. Both methods may have their place in the spectrum of non-invasive monitoring of bronchial inflammation if the optimal exhaled flow is standardized methodologically for the purpose of measurement [Paredi & Barnes, 2010].

The identification of different volatile compounds produced by oxidative stress, nitrosative stress, inflammation and metallic elements, and obtained from the exhaled condensate has also been possible through the use of chromatography and mass spectrometry [Corradi et al. 2007; Corradi et al, 2010]. Some of these compounds may be considered biomarkers in clinical practice [Baraldi et al., 2009 Kostikas et al., 2008; Loukides et al, 2011], such as pH determination [Kostikas et al., 2011; Antus et al, 2010]. However, it is necessary to simplify the instrumentation of the procedure for routine use in clinical practice. The standardization of methodology and applicability to clinical practice of other compounds under investigation as potential biomarkers has yet to be sufficiently achieved due, among other things, to certain limitations, such as contamination of condensate compounds of the mouth (especially if concomitant oral inflammation occurs), difficulty in calculating the optimal dilution of the selected parameter, or instability, volatility, and interaction of the mixture of soluble compounds that can take place during this process [Horváth et al. 2005]. Comparisons with other biomarkers obtained and already standardized are needed to establish the utility of the different compounds of exhaled condensate, especially if
performed one by one [Baraldi et al., 2009]. However, recent specific phenotypes of asthma patients, like aspirin intolerant asthmatics can be identified [Sanak et al, 2011]. Calculating the nasal exhaled fraction may be useful for the study and diagnosis of primary ciliary dyskinesia and is virtually abolished in this disease [Horváth et al., 2003]. On the contrary nasal NO levels are higher in rhinitis [Struben et al., 2006]

3.2.3 The multiple molecular studies of biological lung samples, or systemic samples, significant to pulmonary disease

Since the detection of a single marker of inflammation or oxidative stress does not identify a specific inflammatory disease of the airway as defined today, but rather proves the heterogeneity of inflammatory conditions and diseases of the airway, current research on biological markers focuses on a combination of identifying patterns of proteins and volatile compounds that can be identified by molecular marks or traces they contain. At the molecular level, many omic compounds (proteomic, metabolomic, genomic) may be identified. Within the field of respiratory medicine, these compounds will remain an enigma until the wealth of empirical molecular information is organized and interpreted, free of a priori hypotheses, and the subsequent translation to clinical practice can be carried out. Such information would have the great advantage of producing a custom 'fingerprint' of inflammation during a specific time point in the evolution of the disease process in a particular patient. The correct interpretation of molecular information will allow the clinician to identify and predict the patient and disease biotypes (phenotype and endotype), the severity of the inflammatory process in progress, the clinical evolution, the type of treatment to be applied, the response to the therapy administered, and the prognosis for each individual patient [Crameri, 2005; Vijverberg et al., 2011]. The new molecular application technology based on bioinformatics, cluster analysis, and artificial intelligence algorithms that are being developed at present provide all this information for the purpose of prediction and interpretation at a biological level. This is useful in understanding the new biology of systems integration [Perpiñá, 2010; Scott et al., 2007; Thaler & Hanson, 2005]. The following is a description of the research currently being conducted.

First, chromatography and mass spectrometry have been used to identify hundreds of volatile exhaled organic compounds originating from the metabolic pathways involved in pulmonary biology. However, their use as biomarkers with a clinical application is still under study [Freidrich, 2009]. Secondly, the addition of other specific technology for determining the spectrum of metabolites, proteins or organic compounds in different biological samples (cellular, fluid, or gas) in blood, sputum, or bronchoalveolar lavage, and developed on line, such as the application a multiple set of nanosensors (arrays) or the application of high-resolution nuclear magnetic resonance, has achieved rapid progress in identifying potential profiles and patterns of disease-specific biomarkers. For example, different patterns of compounds originating in breathing and exhaled breath evaluated by the so-called electronic nose identify molecules of different size, volume and dipole [Lewis, 2004]. These patterns have shown good sensitivity and discrimination capabilities for this combination and may be as helpful as those already described for the identification of certain odours, producing an odoriferous mark or smellprint. This would specifically identify the type of inflammation present and could be useful in the differential diagnosis of specific IADs [Dragonieri et al., 2007] in addition to the particular diagnostic and therapeutic strategies for each patient.
4. The future of targeted and individualized biological respiratory therapy

The new concept of biotypes (endotypes and phenotypes) of IAD is transforming the definition of asthma to the point where it will soon be possible to obtain a more accurate simplification of what is understood today as asthma in order to better adapt to patient management and the clinical reality. However, the definition of asthma that currently exists is complex and will remain so, despite continuous modification and rehabilitation, given that although the heterogeneity of the IAD is better understood and the subtypes of the disease and patient subgroups are better classified, the multifactorial and dynamic aspects of the biological responses involved make applying reductionist criteria very difficult. It is therefore necessary to maintain a flexible and mentally versatile attitude that is as dynamic as biology itself. This attitude will facilitate the understanding of respiratory medicine of the future, which in turn will affect therapeutic management. This approach may be considered the cornerstone of individualized therapy for respiratory patients. It will aid in the progressive incorporation of biopharmaceuticals capable of regulating or altering inflammatory pathways, the remodelling process and the smooth muscle response. Both strategies are complementary and briefly commented.

First, the action and biological and immunological mechanisms will modulate the degree of response obtained at the molecular level and will result clinically in a very specific action. Being able to have these modulating biopharmaceuticals will be crucial and improve the quality of life for patients with IAD and asthma [Adock et al., 2008; Casale & Stokes, 2008]. However, the availability of these drugs will lead to a major challenge at the clinical level that they will be reflected in trying to establish well-defined therapeutic indications to ensure safe, efficient, and cost-effective use. Some examples of modulating biopharmaceuticals in the context of eosinophilic inflammation that have been used in patients with poor control and greater severity of symptoms are those that interfere with the biological action of IgE, IL-5 or TNFα. The attainment of adequate control and improvement of outcome in these patients is a sign of success in the development of new molecules, such as the monoclonal antibodies, mepolizumab, etarnercept or omalizumab [Holgate et al, 2011; Pavord et al., 2010; Pelaia et al., 2011]. Other biological modulating drugs acting at the neutrophilic, masto lymphocite cells or other relevant molecules in the pathways and the inflammatory response, are being tested for the purpose of incorporation into the therapeutic arsenal available for IAD [Chung & Marwick, 2010, Barnes, 2009]. Pharmacogenetics and understanding of innate immunitry pathways are promising areas of research to discover determined mechanisms and specific molecules to reverse the altered inflammatory response [Caramori et al., 2004; Kanagaratham et al., 2011; Gupta & Agrawal, 2010; Slager, 2010].

Second, the important thing to considering the therapy of releaving symptoms in the asthma clinic course is the understanding of the mechanical obstruction in the airways and the air-trapping compensatory consequence [Sorkness et al., 2008]. New long-acting smooth muscle relaxant molecules are been incorporated alone or in combination to the inhaler therapy [Cazzola et al., 2011; Chung et al., 2009; Kiyokawa et al., 2011; Postma et al., 2011], but recent knowing of the genetics of airway smooth muscle points out a new strategies to develop asthma targeted molecules [Hai, 2008]. Another specific therapy focus on smooth muscle of the airways, like bronchial thermoplasty, is still under evaluation [Thompson et al., 2011].
5. Conclusion

Inflammatory diseases of the airway, and asthma in particular, are complex and heterogeneous, both in terms of the biological expression of inflammation they produce and in terms of the 'biotypes' (endotypes and phenotypes) that can be objectively translated from this condition. New information provided by new technology applied to modern molecular biology and immunology requires the current concept and definition of asthma to be modified and adapted. The attainment of this important progressive scientific knowledge can help to address how and why this condition occurs and may contribute to a better understanding of the classification of each asthma patient, the proper diagnosis of the type of asthma presented, the monitoring approach, the personalized treatment required, and the method to determine prognosis. A wide spectrum of biomarkers is currently being incorporated as clinically useful parameters. What remains is to gradually adapt them to comprehensive of multidimensional approaches and medical procedures, and establish the appropriate indications and clinical applications in respiratory disease.

6. References


[33] Crapo, RO.; Casaburi, R.; Coates, AL.; Enright, PL.; Hankinson, JL.; Irvin, CG.; MacIntyre, NR.; McKay, RT.; Wanger, JS.; Anderson, SD.; Cockcroft, DW.; Fish, JE. & Sterk, PJ. (2000). Guidelines for methacoline and exercise challenge testing-1999. This official statement of the American Thoracic Society was adopted by the ATS Board of Directors, July 1999. Am J Respir Crit Care Med. Vol.161, No.1, (January 2000), pp. 309-329, ISSN 1073-449X.


[45] Fitzpatrick, AM.; Teague, WG.; Burwell, L.; Brown, MS.; Brown, LA; & NIH/NHLBI Severe Asthma Research Program. (2011b). Glutathione oxidation is associated


[87] Moore, WC.; Meyers, DA.; Wenzel, SE.; Teague, WG.; Li, H.; Li, X.; D'Agostino, R Jr.; Castro, M.; Curran-Everett, D.; Fitzpatrick, AM.; Gaston, B.; Jarjour, NN.; Sorkness, R.; Calhoun, WJ.; Chung, KF.; Comhair, SA.; Dweik, RA.; Israel, E.; Peters, SP.; Busse, WW.; Erzurum, SC.; Bleecker, ER. & The National Heart, Lung, and Blood Institute’s Severe Asthma Research Program. Identification of asthma phenotypes using cluster analysis in the Severe Asthma Research Program. (2010). *Am J Respir Crit Care Med*. Vol.181, No.4, (February 2010), pp.315-323, ISSN 1073-449X.


[100] Puckett, JL.; Taylor, RW.; Leu, SY.; Guijon, OL.; Aledia, AS.; Galant, SP. & George, SC. (2010). Clinical patterns in asthma based on proximal and distal airway nitric oxide categories. *Respir Res*. Vol. 11, (April 2010), p.47, ISSN 1465-993X.


[113] Sorkness, RL.; Bleecker, ER.; Busse, WW.; Calhoun, WJ.; Castro, M.; Chung, KF.; Curran-Everett, D.; Erzurum, SC.; Gaston, BM.; Israel, E.; Jarjour, NN.; Moore, WC.; Peters, SP.; Teague, WG.; Wenzel, SE. & National Heart, Lung, and Blood Institute Severe Asthma Research Program. (2008). Lung function in adults with stable but severe asthma: air trapping and incomplete reversal of obstruction with


[117] Taylor, DR.; Bateman, ED.; Boulet, LP.; Boushey, HA.; Busse, WW.; Casale, TB.; Chanez, P.; Enright, PL.; Gibson, PG.; de Jongste, JC.; Kerstjens, HA.; Lazarus, SC.; Levy, ML.; O’Byrne, PM.; Partridge, MR.; Pavord, ID.; Sears, MR.; Sterk, PJ.; Stoloff, SW.; Szeffler, SJ.; Sullivan, SD.; Thomas, MD.; Wenzel, SE. & Reddel, HK. (2008). A new perspective on concepts of asthma severity and control. *Eur Respir J.* Vol. 32, No. 3, (September 2008), pp.545-554, ISSN 0903-1936.


[122] Verrills, NM.; Irwin, JA.; He, XY.; Wood, LG.; Powell, H.; Simpson, JL.; McDonald, VM.; Sim, A. & Gibson, PG. Identification of Novel Diagnostic Biomarkers for Asthma and Chronic Obstructive Pulmonary Disease. (2011). *Am J Respir Crit Care Med.* Vol.183, No. 12, (June 2011), pp.1633-1643, ISSN 1073-449X.


"Inflammatory Diseases - A Modern Perspective" represents an extended and thoroughly revised collection of papers on inflammation. This book explores a wide range of topics relevant to inflammation and inflammatory diseases while its main objective is to help in understanding the molecular mechanism and a concrete review of inflammation. One of the interesting things about this book is its diversity in topics which include pharmacology, medicine, rational drug design, microbiology and biochemistry. Each topic focuses on inflammation and its related disease thus giving a unique platform which integrates all the useful information regarding inflammation.

How to reference
In order to correctly reference this scholarly work, feel free to copy and paste the following: